Due to the vital roles of PLK4 in the regulation of centrosome replication and the pathology of cancers, more and more PLK4 inhibitors were developed, such as Centrinone, Centrinone-B, CFI-400495 and YLT-11 (Mason et al., 2014; Wong et al., 2015; Kawakami et al., 2018b; Denu et al., 2018; Lei et al., 2018; Kerschner-Morales et al., 2020; Zhao et al., 2021; Singh et al., 2022). Here, PLK4 is linked to cancer.